| Species |
Human |
| Protein Construction |
| Avi |
His |
NKG2A/CD159a (Arg100-Leu233)
Accession # P26715-1 |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized NKG2A/CD159a[Biotin], His & Avi, Human at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind AntiNKG2A Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
18.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
NKG2, also known as NKG2A(CD159A), is a member of the killer cell lectin-like receptor family. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors.It is expressed only in NK-cells, but not in T-cells or B-cells. |
| Synonyms |
NKG2A; NKG2-A; CD94; KLRD1; KP43; KLRC1; CD159A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
